Ruby Mangalindan

This study shows intranasal GHK-Cu treatment reduces cognitive impairment, amyloid plaques, and inflammation in 5xFAD mice, suggesting potential as an AD therapy.

This study shows that intranasal GHK-Cu improves cognitive performance and reduces neuroinflammatory and axonal damage markers in aged mice.

A cocktail of rapamycin, acarbose, and phenylbutyrate slowed aging in mice by improving health metrics and reducing age-related lesions.